Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Total Liabilities
Editas Medicine Inc
Total Liabilities Peer Comparison
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Total Liabilities
$145.9m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$124.4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$38.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$88B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$5.1B
|
CAGR 3-Years
19%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$7.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
See Also
What is Editas Medicine Inc's Total Liabilities?
Total Liabilities
145.9m
USD
Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Total Liabilities amounts to 145.9m USD.
What is Editas Medicine Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
-2%
Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Editas Medicine Inc have been 1% over the past three years , -2% over the past five years .